The global acquired orphan blood diseases therapeutics market size reached US$ 8.8 Billion in 2023. Looking forward, the publisher expects the market to reach US$ 17.2 Billion by 2032, exhibiting a growth rate (CAGR) of 7.7% during 2023-2032. The growing prevalence of blood-related disorders among individuals, favorable government initiatives, and improving healthcare infrastructure worldwide represent some of the key factors driving the market.
Acquired orphan blood diseases are rare blood conditions that are caused by an inability to produce red blood cells (RBCs) or their insufficiency in the blood. They comprise numerous diseases, such as myelodysplastic syndrome (MDS), idiopathic thrombocytopenic purpura (ITP), paroxysmal nocturnal hemoglobinuria (PNH), myelofibrosis (MF), polycythemia vera (PV), and acquired agranulocytosis. They can cause improper functioning of bone marrow and can decrease the number of platelets. As they can be treated through several therapies, such as recombinant factor, immunoglobulin infusion therapy, activated prothrombin complex concentrate, and thrombopoietin receptor agonists, the demand for acquired orphan blood disease therapeutics is rising across the globe.
Acquired orphan blood diseases are rare blood conditions that are caused by an inability to produce red blood cells (RBCs) or their insufficiency in the blood. They comprise numerous diseases, such as myelodysplastic syndrome (MDS), idiopathic thrombocytopenic purpura (ITP), paroxysmal nocturnal hemoglobinuria (PNH), myelofibrosis (MF), polycythemia vera (PV), and acquired agranulocytosis. They can cause improper functioning of bone marrow and can decrease the number of platelets. As they can be treated through several therapies, such as recombinant factor, immunoglobulin infusion therapy, activated prothrombin complex concentrate, and thrombopoietin receptor agonists, the demand for acquired orphan blood disease therapeutics is rising across the globe.
Acquired Orphan Blood Diseases Therapeutics Market Trends:
At present, the increasing awareness about blood diseases and their treatment options among the masses, along with the inflating income level of individuals worldwide, represents one of the major factors influencing the market positively. Moreover, the rising demand for blood disease therapeutics options due to the increasing geriatric population is strengthening the growth of the market. In line with this, governing agencies and private organizations of various countries are encouraging the adoption of blood disease therapeutics by spreading awareness about the occurrence of blood-associated disorders among individuals and offering several healthcare initiatives around the world is impelling the growth of the market. Apart from this, the growing adoption of blood disease therapeutics due to the increasing prevalence of various blood-related disorders among individuals across the globe is offering a positive market outlook. Additionally, the wide availability of acquired orphan blood disease therapeutics drugs through online and offline pharmacy stores around the world is contributing to the growth of the market. Besides this, the increasing demand for personalized medicines among individuals, along with the improving healthcare infrastructure worldwide, is offering lucrative growth opportunities to industry investors. In addition to this, there is a rise in the demand for cost-effective and quality care solutions among individuals across the globe. This, coupled with the increasing adoption of preventative care and wellness services to avoid widespread disease among individuals, is bolstering the growth of the market. Furthermore, key manufacturers are introducing hydroxyurea-based treatment for pediatric patients with sickle cell anemia, which is supporting the growth of the market.Key Market Segmentation:
The publisher provides an analysis of the key trends in each segment of the global acquired orphan blood diseases therapeutics market, along with forecasts at the global, regional, and country levels from 2024-2032. The report has categorized the market based on therapy, disease indication, and distribution channel.Therapy Insights:
- Recombinant Factor
- Immunoglobulin Infusion Therapy
- Activated Prothrombin Complex Concentrate
- Thrombopoietin Receptor Agonists
- Others
Disease Indication Insights:
- Acquired Agranulocytosis
- Acquired Hemophilia
- Acquired Von Willebrand Syndrome
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Myelodysplastic Syndrome
- Others
Distribution Channel Insights:
- Hospital Pharmacy
- Retail Pharmacy
- Others
Regional Insights:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global acquired orphan blood diseases therapeutics market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Alexion Pharmaceuticals Inc. (AstraZeneca plc), Amgen Inc., GSK plc, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical Co. Ltd., Rigel Pharmaceuticals Inc., Roche Holding AG, Sanofi, Takeda Pharmaceutical Company Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.Key Questions Answered in This Report:
- How has the global acquired orphan blood diseases therapeutics market performed so far, and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global acquired orphan blood diseases therapeutics market?
- What is the impact of each driver, restraint, and opportunity on the global acquired orphan blood diseases therapeutics market?
- What are the key regional markets?
- Which countries represent the most attractive acquired orphan blood diseases therapeutics market?
- What is the breakup of the market based on the therapy?
- Which is the most attractive therapy in the acquired orphan blood diseases therapeutics market?
- What is the breakup of the market based on the disease indication?
- Which is the most attractive disease indication in the acquired orphan blood diseases therapeutics market?
- What is the breakup of the market based on the distribution channel?
- Which is the most attractive distribution channel in the acquired orphan blood diseases therapeutics market?
- What is the competitive structure of the global acquired orphan blood diseases therapeutics market?
- Who are the key players/companies in the global acquired orphan blood diseases therapeutics market?
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Acquired Orphan Blood Diseases Therapeutics Market
6 Market Breakup by Therapy
7 Market Breakup by Disease Indication
8 Market Breakup by Distribution Channel
9 Market Breakup by Region
10 Drivers, Restraints, and Opportunities
12 Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Alexion Pharmaceuticals Inc. (AstraZeneca plc)
- Amgen Inc.
- GSK plc
- Novartis AG
- Novo Nordisk A/S
- Otsuka Pharmaceutical Co. Ltd.
- Rigel Pharmaceuticals Inc.
- Roche Holding AG
- Sanofi
- Takeda Pharmaceutical Company Limited
Methodology
LOADING...
